Field-ready portable rapid nucleic acid test for tuberculosis detection and drug-resistance profiling in resource-limited settings

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, with over a million deaths annually and a growing threat from multidrug-resistant strains (MDR-TB). A major bottleneck in controlling TB is the lack of truly portable, rapid, and user-friendly diagnostic systems that can operate effectively in decentralized, resource-constrained settings. Here, we present a first-of-its-kind, portable nucleic-acid-based diagnostic platform that enables both primary TB screening and detection of drug resistance within the same unified framework, without any change in the operative embodiment. The system integrates loop-mediated isothermal amplification (LAMP) targeting dual Mycobacterium tuberculosis markers (IS6110 and IS1081) with a compact, AI-enabled device and smartphone-based readout, delivering rapid and reliable results at the point-of-care. Clinical evaluation across 105 samples demonstrated high sensitivity and specificity. Further validation through real-world deployment in a primary healthcare setting, using a single-gene (IS6110) configuration operated by minimally trained personnel, yielded 95.60% sensitivity and 100% specificity, benchmarked against GeneXpert. Critically, the same platform architecture, without modification, extends seamlessly to drug-resistance profiling, demonstrated here through a probe-free, allele-specific LAMP approach for identifying key mutations associated with rifampicin (rpoB) and isoniazid (katG) resistance. By combining robust molecular diagnostics with AI-driven automation in a compact and accessible format, this work represents a significant medical advancement toward democratizing TB care. The platform thus holds strong potential to enable early screening, guide timely treatment decisions, reduce transmission, and substantially strengthen global TB elimination efforts, particularly in high-burden, low-resource settings.